Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9097642 | 0.86 | MLYCD (0.42) | ALDH1A1KMT2ACYP3A4HIF1APDPK1 | |
| SCHEMBL29287654 | 0.82 | ALDH1A1 (0.49) | ALDH1A1KMT2ACYP3A4HIF1AMLYCD | |
| SCHEMBL19235630 | 0.82 | MLYCD (0.57) | ALDH1A1KMT2AMLYCDAPPHSP90AA1 | |
| Water SCHEMBL11237464 | 0.81 | ALDH1A1 (0.48) | ALDH1A1KMT2ACYP3A4HIF1AMLYCD | |
| Water SCHEMBL11237487 | 0.81 | ALDH1A1 (0.48) | ALDH1A1KMT2ACYP3A4HIF1AMLYCD | |
| SCHEMBL933209 | 0.79 | ALDH1A1 (0.50) | ALDH1A1KMT2ACYP3A4HIF1AMLYCD | |
| SCHEMBL3073313 | 0.78 | KMT2A (0.49) | ALDH1A1KMT2ACYP3A4HIF1AMLYCD | |
| SCHEMBL12083098 | 0.78 | MLYCD (0.42) | ALDH1A1KMT2ACYP3A4HIF1AMLYCD | |
| SCHEMBL20613 | 0.78 | ALDH1A1 (0.49) | ALDH1A1KMT2ACYP3A4HIF1AMLYCD | |
| SCHEMBL12550506 | 0.76 | HSP90AA1 (0.47) | ALDH1A1KMT2ACYP3A4HIF1AAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1075 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12529704-B2 | Methods for objective assessment of stress, early detection of risk for stress disorders, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2026-01-20 | — | — | US | claimed |
| US-12458694-B2 | Methods for treatment of accelerated atherosclerosis and rheumatoid arthritis with an anti-Apo B100 antibody | ABCENTRA, LLC (US) | 2025-11-04 | — | — | US | claimed |
| US-12310934-B2 | Methods of treatment of spontaneous preterm birth | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-27 | — | — | US | claimed |
| US-20240226289-A9 | COMPOSITIONS AND METHODS FOR TREATMENT OF RHEUMATOID ARTHRITIS AND ACCELERATED ATHEROSCLEROSIS | ABCENTRA, LLC | 2024-07-11 | — | — | US | claimed |
| US-20240226000-A9 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | DYVE BIOSCIENCES, INC. | 2024-07-11 | — | — | US | claimed |
| US-20240130962-A1 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | DYVE BIOSCIENCES INC (US) | 2024-04-25 | — | — | US | claimed |
| US-20240131153-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF RHEUMATOID ARTHRITIS AND ACCELERATED ATHEROSCLEROSIS | ABCENTRA LLC (US) | 2024-04-25 | — | — | US | claimed |
| US-20230381173-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR TREATING DISEASES | TONGLI BIOMEDICAL CO., LTD. (CN) | 2023-11-30 | — | — | US | claimed |
| EP-4277616-A1 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | Dyve Biosciences, Inc. (US) | 2023-11-22 | — | — | EP | claimed |
| US-11690912-B2 | Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody | ABCENTRA, LLC (US) | 2023-07-04 | — | — | US | claimed |
| US-20070105848-A1 | Methylene Blue Therapy of Parasitic Infections | BIOENVISION, INC. | 2007-05-10 | — | — | US | claimed |
| EP-1778143-A2 | SULFONATED STYRENE POLYMERS FOR MEDICAL ARTICLES | Aegis Biosciences, LLC (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2007038201-A1 | METHYLENE BLUE THERAPY OF PARASITIC INFECTIONS | BIOENVISION, INC. (US) | 2007-04-05 | — | — | WO | claimed |
| US-20060292208-A1 | Sulfonated styrene polymers for medical articles and barrier web constructs | AEGIS BIOSCIENCES, LLC (US) | 2006-12-28 | — | — | US | claimed |
| US-20060178691-A1 | Methods and devices to curb appetite and/or reduce food intake | THE DIRECTOR OF DEVELOPMENT OF THE STATE OF OHIO | 2006-08-10 | — | — | US | claimed |
| WO-2006017245-A2 | SULFONATED STYRENE POLYMERS FOR MEDICAL ARTICLES | AEGIS BIOSCIENCES, LLC (US) | 2006-02-16 | — | — | WO | claimed |
| EP-1545458-A2 | BUCCAL, POLAR OR NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING AN INFECTIOUS DISEASE OR CANCER | Novadel Pharma Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2004019912-A2 | BUCCAL, POLAR OR NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING AN INFECTIOUS DISEASE OR CANCER | NOVADEL PHARMA INC. (US) | 2004-03-11 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12529704-B2 | Methods for objective assessment of stress, early detection of risk for stress disorders, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs | DDB1, DDX6, DDX21 | ALDH1A1 2490/4885KMT2A 3735/4885CYP3A4 1221/4885 |
| US-20070105848-A1 | Methylene Blue Therapy of Parasitic Infections | TPMT, MB, CD68 | ALDH1A1 740/4885KMT2A 2480/4885CYP3A4 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.